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Abstract |   
Harmonious interactions between radiation, medical, interventional and surgical oncologists, as well 
as other members of multidisciplinary teams, are essential for the optimisation of patient care in 
oncology. This motivation is particularly important in the current landscape, in which standard-of-care 
approaches to cancer treatment are evolving towards highly targeted treatments, precise image 
guidance and personalised cancer therapy. Herein, we highlight the importance of multidisciplinarity 
and interdisciplinarity at all levels of clinical oncology training. Potential deficits in the current career 
development paths and suggested strategies to broaden clinical training and research are presented, 
with specific emphasis on the merits of trainee involvement in functional multidisciplinary teams. 
Finally, the importance of training in multidisciplinary research is discussed, with the expectation that 
this awareness will yield the most fertile ground for future discoveries. Our key message is for cancer 
professionals to assume their duty in ensuring that trainees appreciate the importance of 




Communication across different specialties remains a core element of cancer care. Communication 
skills are important in establishing a good relationship with patients, but in the increasingly complex 
field of cancer treatment, oncologists from each specialty need to be equally skilled at communicating 
with, and learning the art of, those focused on other specialties. One current view is that four ‘pillars’ 
exist in oncology: radiation oncology, medical oncology, interventional oncology and surgical 
oncology, with some degree of interdependence between all four disciplines (FIG. 1). Nearly all 
patients will come into contact with clinicians practising one or more of these specialties during their 
cancer care continuum. To achieve the best outcomes for patients, expertise relating to these four 
pillars needs to be integrated and combined wisely, and all treatment options need to be considered 
to provide an optimal care pathway for each patient. This approach should also drive innovation and 
efficient use of health-care resources across populations.  
 The length and scope of oncology training varies between health-care systems, but typically 
specialization in radiation and medical oncology requires 4–5 years of clinical training to obtain 
accreditation from a national regulating body, such as the Royal College of Radiologists (RCR) in the 
UK, or the American Board of Internal Medicine (ABIM) in the USA.  Surgical oncology and 
interventional oncology training can vary between 4-8 years.  These timescales for clinical training do 
not include time taken out of specialist training to experience research or undertake an higher degree. 
Trainees usually follow a systems-based or organ-based syllabus to study different tumour sites and 
practical procedures (particularly in the specialties of radiation, surgical and interventional oncology). 
The proportion of oncology trainees undertaking full-time research varies widely between countries 
and regions. This research can be either laboratory-based or clinical, and can lead to the award of a 
higher research degree or in securing medium-term placements to learn specific skills, such as 
stereotactic radiotherapy or radiofrequency ablation (FIG. 2).  
 Similarly to the patterns observed for many medical specialties, the proportion of female 
trainees and specialists in oncology has increased over the years. The ASCO State of Cancer Care in 
America report notes that the proportion of females in all oncology specialties continues to rise, and 
in 2015, 46% of trainees in oncology fellowship programmes were female[1]. In the UK, the RCR 2014 
workforce census recorded that 65% of clinical oncology trainees were female, compared with 46% of 
consultants at that time[2]. Of note, 25% of consultants included in the census worked less than full-
time, with this figure rising to 40% for female consultants. As well as having implications for workforce 
planning, this disparity highlights the need to ensure training, academic work and family circumstances 
are balanced to enable each individual to achieve a work–life balance that maximises satisfaction and 
productivity, while meeting the patients’ care needs. General surgery is attracting a growing 
proportion of female trainees around the world, although they remain in the minority compared to 
male surgical trainees; this gender gap is even more pronounced for non-white female trainees[3]. In 
the UK, the proportion of female surgical trainees increased from 15% in 2009 [4] to 28% in 2013 [5]. 
 Cancer services are encountering significant challenges in the current health-care climate, 
which relate to rapid advances in the development of novel therapies, escalating costs of interventions 
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and ageing populations[6]. Current financial constraints limit access to cancer therapies, and shortfalls 
in the required numbers of trained oncologists are expected in several countries owing to poor 
workforce planning [7]. In order to achieve the best possible care for all patients, the current deficits 
in the training of cancer specialists must be recognized, and strategies for optimized multidisciplinary 
training must be defined.  
 
[H1] Clinical training  
Clinical training should provide oncologists with a standard toolkit with which to approach the care of 
all patients with cancer and the toolkit should be tailored to each discipline’s common and local 
practice. Data-driven clinical trials should be a driving force for progress in clinical oncology; training 
in regulatory and clinical trial science and administration will facilitate the incorporation of clinical 
trials into oncology care in the future. Academic translational efforts in conducting phase I–III oncology 
drug trials should be combined with innovations in medical devices, and an increasing proportion of 
clinical trials should be focused on a rational methodology for combining drugs, devices, radiotherapy 
and imaging guidance for local therapy.  An example is the phase I-III clinical trial advancement of 
yttrium-90 microspheres combined with chemotherapy, achieved by radiation oncologists, medical 
oncologists and interventional oncologists working collaboratively [8, 9]. Such demonstrations of 
academic multidiscplinarity in practice send a clear message to trainees on how collaboration can 
strengthen research and clinical practice.  
 The current reality is that clinical research is often conducted within independent silos of 
research and clinical conferences, with different specialties having varying levels of appreciation of 
emerging therapies in other disciplines. A basic understanding of clinical and translational research 
should be mandated by all training programmes — for example, as part of the ‘core competencies’ 
governed by the Accreditation Council for Graduate Medical Education (ACGME) in the USA[10]. By 
making this aspect of training mandatory, more oncologists will become familiar with the ethics and 
regulatory science of clinical trials.  
 
Several professional organizations have a multidisciplinary teaching role (BOX 1). These initiatives are 
breaking new ground by developing cross-speciality courses but further developments are required. 
Most innovation in cancer care continues to originate from specialist organizations, such as the 
European Organisation for Research and Treatment of Cancer or the Radiation Therapy Oncology 
Group, which generally remain predominantly oncology-focused and specialty-specific. Because 
innovation in academia has run along speciality-specific tracks, innovation in industry has tended to 
proceed in parallel rather than in synergy and hence academic training, siloed from commercial 
partners, has generally not benefitted from the expertise of industry. Improvements in cross-specialty 
integration with industry partners could potentially offer the ability to steer innovation and 




[H2] Radiation oncology 
Radiation oncology is a specialty focused on the assessment of patients receiving radiotherapy, and the 
technical design, delivery and overall optimization of these therapeutic approaches. In the UK and other 
countries, many oncologists are dually trained in radiation and medical oncology, in a discipline termed 
‘clinical oncology’. Specialization in radiation or clinical oncology in the UK, USA, Australia and New 
Zealand typically requires 5 years of training designed to impart knowledge of the physics, anatomical 
and pharmacological aspects integral to these disciplines. Proficiency in these areas is tested with 
formal examinations, such as those conducted by the RCR in the UK and the RANZR in Australia and 
New Zealand. Research is not mandatory in most training schemes, but is increasingly encouraged to 
foster a better understanding of the changing therapeutic landscape in oncology.  
 In all countries, radiation oncology trainees benefit from a multidisciplinary approach involving 
close liaison with radiographers and radiation therapists (allied health professionals who deliver the 
radiotherapy), and physicists and dosimetrists (who plan the technical aspects of treatment). Radiation 
oncology trainees are increasingly required to receive advanced training in radiology, however, because 
current treatments are commonly guided by daily imaging scans. The most frequently used imaging 
modality is CT, but magnetic resonance (MR)-based approaches are also being developed[11]. In the 
absence of radiation oncologist with the necessary training in advanced radiology skills, including those 
relating to novel imaging techniques[12, 13], the recurrence rates of patients with cancer might 
increase, owing to inadequate tumour delineation or ‘geographical misses’. The faculty at Duke 
University Medical Centre have therefore designed a specialist radiology training programme for its 
radiation oncology residents[14]. This type of training is currently an unmet need in many oncology 
subspecialties: in the 2013 Annual Survey of UK Clinical Oncology trainees, only 2.6% reported they had 
received formal radiology training from a radiologist, and 35% had ‘self-taught’ the radiology skills they 
needed in clinical practice[15]. Faculty in charge of future training of radiation oncologists should 
identify potential synergies with radiology teaching schemes, in order to improve the training in both 
specialties.  
 Trainees in radiation oncology also need to learn how to respect and work with interventional 
radiologists and medical oncologists. New paradigms in radiation treatment, such as the radical 
treatment of oligometastases with stereotactic body radiotherapy[16, 17], require close integration 
between oncologists from a range of disciplines who also have the ability to deliver ablative treatments, 
to ensure that the patient receives the most-appropriate treatment. For example, radiofrequency 
ablation[18], which can be delivered by interventional or surgical oncologists, is an alternative to 
stereotactic body radiotherapy for some patients. Thus, all oncologists need to develop a good 
understanding of alternative ablative treatments (such as microwave, laser, cryoablation, or focused 
ultrasonography for thermal ablation) in order to optimize care for patients. Likewise, combinations of 
targeted agents (such as sunitinib) and radiotherapy might result in improvements in cancer control. 
Hence, close collaboration between radiation oncologists and medical oncologists is required to 
maximise benefits of radiotherapy combinations with other therapeutic modalities, and to minimize 
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the risk of adverse events associated with treatment modalities that might potentiate radiotherapy 
toxicity [19].  
 
[H3] Research within clinical training programmes. 
Access to full-time research fellowships during training is limited and highly competitive. In most health-
care systems, dedicated research time is not contemplated as a priority in training programmes. Indeed, 
data from a small survey indicate that trainees who do not conduct full-time research publish an 
average of less than one peer-reviewed article prior to becoming a consultant [20] supporting our belief 
that for academic outputs to flourish, dedicated research time within training is required. Since 2005, 
trainees in radiation oncology in Australia and New Zealand have been mandated to complete at least 
one piece of independent research of ‘publishable quality’ as part of their training, although this 
requirement is not supported by allocation of protected research time. A survey of 116 trainees in these 
countries published in 2014 revealed that 53% had published research in a peer-reviewed journal, and 
59% had presented their work at an international meeting[21]. For some of these trainees, the 
encouragement to conduct academic work could foster career-long enthusiasm for research; thus, the 
effectiveness of other training schemes might be improved using this approach.  
 In order to pursue high-quality research, however, individuals need dedicated research time, 
both during training and after certification as a specialist. For future oncologists to run practice-
changing trials, research training needs to be met. In the USA, the need for a formal clinical trial training 
programme has been identified in response to data showing that many trainees lack confidence in 
clinical trial design[22]. In the UK, the Academic Clinical Fellow (ACF) radiation oncology training 
programme incorporates dedicated time for research, enabling trainees to spend time in the laboratory 
or on a full-time clinical research project[23]. In the Netherlands, all trainees spend at least 10% of their 
residency time engaged in full-time research, and many have completed a PhD in a related discipline 
before starting their radiation oncology training.  
 
[H2] Medical oncology  
When the ESMO was first established in 1975, its founders defined seven core principles[24] (BOX 2), 
many of which focused on the importance of multidisciplinary care. These principles should remain a 
driving force in medical oncology training, because they reflect the current key areas of training: 
clinical and translational research, acquisition of clinical skills, and the ability to establish effective and 
fit-for-purpose clinical and research networks. 
 
[H3] Clinical training programmes.  
Medical students considering a career in medical oncology often gain only limited experience in this 
discipline at medical school. In Europe, both ESMO and the European School of Oncology (ESO) have 
recognized this problem and currently run a joint 5-day residential course that is available to medical 
students who wish to gain more insight into medical oncology [25]. By offering this intensive 
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educational programme, ESMO and ESO aim to motivate medical students to commit to working for 
the benefit of patients with cancer in the fast-evolving field of medical oncology.  
 In most countries, including the UK, training of medical oncologists is structured as a 4-year 
specialist programme, with trainees rotating through supervised posts, in which they are involved in 
caring for patients with common tumour types (such as gastrointestinal, breast or lung cancers), to 
cover the core syllabus set out by the training boards. The introduction of postgraduate structured 
exams by the UK Royal College of Physicians (RCP), ESMO and the ABIM has enabled the core syllabi 
to gain international recognition, and guarantees that accredited medical trainees obtain harmonized 
clinical knowledge before completing their training.  
 The future needs of medical services are difficult to predict, but undoubtedly the demands 
on cancer services as a whole will increase as a result of the ageing population demographics 
worldwide. This demographic trend will also necessitate broader understanding of the additional 
challenges relating to cancer care specifically in the elderly population. Joint training programmes in 
geriatrics and oncology do exist worldwide, but remain limited. The need for such training was first 
identified in the USA in the 1990s[26], and the introduction of similar programmes in some European 
countries, e.g. France, followed shortly after [27, 28]. Both ASCO [29] and ESMO [30]have now 
published specific guidelines on cancer therapies for the elderly, an international society has been 
established [31] and pilot schemes exist to address the unmet training needs related to this previously 
under-represented area. Certain countries, including the UK, may have fallen behind by taking a less 
proactive approaches than those adopted in the USA and European countries (among others)[32] and 
this could be addressed by including tools for geriatric assessment in all training schemes[33].  
 Although not considered traditional pillars of cancer care, clinical genetics, immunology and 
molecular pathology are specialties that have become critical to delivering patient-centric cancer care. 
Over the past decade, the proliferation of tissue-based and blood-based biomarkers of prognosis or 
response to treatment has increased dramatically for example in lung cancer [34]. Patient stratification 
on the basis of mutations in cancer-related genes is now a reality in clinical trials, and molecular criteria 
determine patient access to treatments outside clinical trials. The expanding use of immunotherapies, 
particularly immune-checkpoint inhibitors, in clinical practice means that knowledge of immunology 
is becoming increasingly important for all oncologists to evaluate the full range of treatment options 
available and to manage the adverse events associated with immunotherapies [35, 36].  
 Another important discipline for which training varies widely between countries is palliative 
care. In many respects, training in palliative care gives oncologists a broader perspective on patient 
care than any of the other disciplines because they have to learn about managing pain and other 
symptoms, as well as the importance of considering the patient’s physical, psychosocial and spiritual 
wellbeing. Palliative care is delivered in a variety of settings, including hospices, hospitals and the 
community, which creates challenges in training oncologists adequately in this discipline. Despite this 
potential barrier, the management of symptoms in patients with cancer is acknowledged as a key 
aspect of training; thus, the Joint RCP Training Board in the UK has prioritized training in palliative care 
within the medical oncology curriculum [37].  
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[H3] Improving trainee access to clinical and translational research.  
Traditionally, medical oncologists have tended to have more opportunities to perform clinical and 
translational research than other oncologists, and approximately 75% of medical oncology trainees 
will undertake a higher research degree [38]. In the current worldwide financial climate, however, 
securing funding for such endeavours has become increasingly challenging for clinicians. In the UK, 
most funding for junior clinical fellowships comes from cancer charities, such as Cancer Research UK 
(CRUK), or large medical research charities, such as the Medical Research Council and Wellcome Trust. 
In the USA, early career clinicians are eligible for prestigious government-sponsored funding 
opportunities, such as the NIH Mentored Clinical Scientist Research Career Development Award (K08) 
[39], Early Investigator Award, and Patient-Oriented Research Career Development Award (K23) [40], 
which allow clinicians to dedicate a 3–5 year period of their career to intense, supervised research as 
a pathway to autonomy, and with the ultimate aim of educating a future generation of NIH 
researchers.  
 The competition for obtaining these early career grants is fierce and, somewhat paradoxically, 
previous experience in laboratory research considerably improves the prospects of successful 
application. Without funding, trainees often cannot leave clinical training positions to gain experience 
in the laboratory. As mentioned previously, the UK ACF programme (FIG. 3) might better prepare 
trainees for the competitive world of academic medicine, and should, therefore, be made available to 
an increased number of trainees.  
 Clinical research is a valuable component of training that, unfortunately, is often incorporated 
ad hoc into clinical training programmes. Few trainees have the opportunity to work in large early 
clinical trials units, but such experience is an important aspect of the professional development of 
future oncologists. Access to local research networks and first-hand experience in trials units will 
facilitate oncologists in referral of well-selected patients for enrolment in clinical trials. If fellowships 
in such units are not possible, trainees should have access to local research networks, and the 
opportunity to participate in multidisciplinary forums for local research, such as a the pan-UK Cancer 
Research Network [41].  
 
[H2] Interventional oncology 
Despite health-care system deficiencies, vascular and interventional radiology (VIR) with specific 
application to cancer care have fostered the subspecialty of interventional radiology with specific 
application to cancer care, which overlaps substantially and synergizes with the other three pillars of 
oncology. Previously, these types of interventional procedures were mainly associated with 
symptomatic control and palliative or supportive care but, at present, interventional oncology is 
increasingly used with the goals of increasing patient survival and/or cure rates of certain cancers[42], 
such as liver cancer or renal cell carcinoma [43], which can be achieved using cryoablation or thermal 
ablation with radiofrequency, microwave, or laser electromagnetic radiation. Interventional oncology 
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has become a vibrant and dynamic component of most interventional radiology practices, aimed at 
standardizing the use of multidisciplinary personalized therapies.  
The Society of Interventional Radiology (SIR) in the USA [44], and the Cardiovascular and 
Interventional Radiology Society of Europe [45] have promoted adoption and harmonization of clinical 
practice guidelines and reporting standards, and organized training symposiums and workshops to 
discuss paradigms in interventional oncology. In addition, education and cross-disciplinary training in 
minimally invasive, image-guided, locally and regionally delivered cancer therapies has been the main 
goal of numerous large meetings and multidisciplinary conferences, such as the World Conference on 
Interventional Oncology [46], European Conference on Interventional Oncology [47], Synergy [48], 
Symposium on Clinical Interventional Oncology [49], and Interventional Oncology Sans Frontieres [50]. 
These meetings promote multidisciplinary attendance by often offering free or discounted registration 
to partners from the host institution.  
 The three other oncology subspecialities are increasingly recognising the importance of 
interventional oncology. The RCR Sub-Faculty Board, for example, have stated that such training 
should be included in the clinical oncology curricula[51]. New techniques, such as selective internal 
radiotherapy treatment, require the skills of both oncologists and interventional radiologists for 
optimal patient selection, treatment and follow-up assessment[52]. Acquiring such skills can be 
difficult because a limited number of centres offer these services, and not every oncologist needs to 
be proficient in the techniques themselves. Nevertheless, a familiarity with interventional techniques 
will enable the appropriate selection of patients from all centres, thus improving access to these 
pioneering techniques. 
 Postgraduate training needs to evolve constantly in order to adapt to rapidly changing 
treatment paradigms. In previous decades, minimally invasive, image-guided therapies (for example, 
ablation and chemoembolization) have been increasingly integrated into the treatment algorithms for 
many cancers, with prominent roles for these modalities promulgated in National Comprehensive 
Cancer Network guidelines and various treatment algorithms for neoplasms of the liver, kidney, bone, 
and lung. These locally and regionally delivered interventional oncology therapies are most-commonly 
administered by physicians trained in VIR or interventional body imaging (a specialty within diagnostic 
radiology), who often lack formal independent dedicated or structured training in interventional 
oncology. The interventional radiology fellowship has traditionally been a 1-year fellowship after 
radiology residency; however, this short-term fellowship alone is clearly not sufficient to learn the 
requisite clinical and technical skills, owing to the rapid expansion of this specialty with enormous 
technological and scientific advances in areas including interventional oncology[53].Traditionally, VIR 
specialists receive fellowship training encompassing interventional oncology after a diagnostic 
radiology residency, but the extent of the oncology training experience widely varies across VIR 
fellowships. In 2013, the US ACGME approved an independent residency pathway for VIR training and 
primary certification [54]. Future US trainees will be able to receive VIR and/or interventional oncology 
training via a fellowship, or through an integrated or independent VIR residency pathway. Thus, medical 
students can enter VIR residency directly, or VIR fellowship or residency after completing a diagnostic 
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radiology residency (6–7 years of postgraduate training). The ‘Residents, Fellows and Student’ section 
of the SIR promotes training opportunities in interventional oncology at multiple levels [55], and the 
Medical Student Council of the SIR serves future students interested in interventional oncology within 
interventional radiology [25].  
 In addition, US clinical office-based care reimbursement coding for interventional radiology 
physicians increased 1,200% between 1998–2008[56]. In the USA, interventional radiology is 
transitioning to an independent residency status, which will result in improved procedural and clinical 
training of interventional radiologists, without affecting the number of post-graduate years they spend 
in training (total 6–7 years). This transition will also enable medical students to enter directly into the 
interventional radiology specialty through multiple pathways. The most important aspect of this 
transition will be the increase in clinical training, because interventional radiology trainees will perform 
rotations with their surgical and medical colleagues in oncology and intensive care, among other 
subspecialties. Nevertheless, imaging, procedures, and nonprocedural clinical care remain the three 
basic facets of the interventional radiology training pathway[56]. 
 Interventional radiology has never been a more popular specialty among medical trainees than 
it is today. Between 2009–2013, the uptake of available fellowship positions increased from 54% to 
>90% in the USA[57]. Unfortunately, interventional radiology is not one of the six basic clinical rotations 
that all medical students must undertake in US medical schools, and only up to 25% of schools require 
a rotation in diagnostic radiology[58]. Surveys conducted with medical students indicate that <1% of 
them require conduction of a VIR rotation. The results of studies performed in the USA, European 
countries and Canada have demonstrated a general lack of knowledge of interventional radiology 
among medical students[57]. As interventional oncology becomes a larger discipline within 
interventional radiology, the exposure of students earlier in their careers to the existence and 
uniqueness of multidisciplinary interventional oncology is critical for this emerging discipline to assume 
a role in multidisciplinary team training. With the designation of specialty status for VIR by the American 
Board of Medical Specialties in the USA [54] and the recognition of VIR as an emerging subspecialty of 
radiology in the UK[42], further integration of interventional oncology into multidisciplinary care will 
maintain and even increase the strength of the fourth and newest pillar of cancer care. 
 
[H2] Surgical oncology 
One of the demands for contemporary training in surgery is to produce fully qualified surgeons who 
are aware of the particular needs associated with clinical oncology and who are capable of working 
functionally within complex multidisciplinary teams. The expertise of surgeons should include a blend 
of technical ability (with subspecialty skills), knowledge of oncology treatments, and the capability of 
enrolling patients into randomized clinical trials in high volumes. For example, three-quarters of the 
41,000 newly diagnosed patients with colorectal cancers each year in the UK undergo surgical 
treatment for their cancer, but <10% of these enrol in a clinical trial[59]. Poor trial enrolment rates 




[H3] Technical skills in surgical oncology. Surgical oncologists are trained to a high standard in the 
prevention, diagnosis, treatment and rehabilitation of patients with cancer. These principles are 
championed by two pan-specialty umbrella organizations, the Society of Surgical Oncology in North 
America and the British Association of Surgical Oncology in the UK. Trainee-led groups exist within these 
organizations, including the Surgical Oncological Trainee Association [60] which promotes the needs 
and oncology-focused education of future surgeons.  
 Specialty-specific oncology training programmes are integrated into current surgical training, 
which are supplemented by fellowships bridging the gap between senior trainees and established 
consultants[61]. Fellowships on laparoscopic surgery are provided for senior trainees with 
gynaecological, urological and colorectal expertise; these fellowships have international scope (for 
example, the European Society of Coloproctology (ESCP) offers pan-European colorectal fellowships). 
Similar high-quality training fellowships are available across all surgical oncology subspecialties, on 
aspects including oncoplastic breast surgery, international travelling fellowships for gastroesophageal 
resection, minimally invasive urological training and ocular oncology. 
 Surgical training needs to keep pace with the rapid evolution of new technologies and 
multidisciplinary team working. For example, the British Association of Plastic and Reconstructive and 
Aesthetic Surgeons endorse courses in sentinel-lymph-node biopsy in patients with malignant 
melanoma, and simulator models have been developed for teaching sentinel-node biopsy in patients 
with breast cancer. Similar courses are delivered by the Cleveland Clinic and other large cancer 
institutions in the USA. Robotic surgery for urological, neurosurgical, neck, gynaecological and 
colorectal cancer is evolving, and robotic training courses and fellowships are already available. Current 
challenges in robotic surgery include the achievement of cost-effectiveness and real patient benefits. 
Assessment of the effects of these novel technologies on patient outcomes includes both registry-based 
commissioning and randomized clinical trials for new technologies[62], in concordance with the IDEAL 
Collaboration’s recommendations for evaluation of surgical innovation[63]. Currently, a limited number 
of patients access such programmes and, therefore, deficits in the tutelage of trainees in the 
importance of clinical and economic benefit assessment must be addressed. 
 
[H3] Translational research skills.  
All surgical trials face recruitment challenges[62], illustrating the need to improve surgical oncology 
training not only in the UK, but also worldwide. Surgical training currently supports the development 
of skills required to conduct clinical trials among both dedicated academic and non-academic clinical 
trainees; hopefully, newly trained consultant surgeons emerging from these programmes will recruit 
patients into randomized trials as part of routine practice, with the aim that every patient undergoing 
surgery should be offered the opportunity to partake in a trial. Indeed, this skillset is starting to be 
incorporated into training programmes, with Good Clinical Practice certification [64] and the definition 
of milestones, such as a minimum number of recruited patients [65]. Trainee surgeons are supported 
within national cancer networks — for example, trainee members are part of the surgical subgroups of 
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the UK National Cancer Research Institute. These members actively contribute to designing and 
conducting new trials. For example, the management groups of both the STAR-TREC and FOXTROT trials 
include surgical and oncological trainees who are shadowing their senior counterparts and are working 
together to contribute to funding applications[66].  
 In the UK, surgical trainees have pioneered trainee-led research collaboratives[67], which are 
regional and national networks of trainees connected by their annual rotations, and have been involved 
in planning and delivering multisite research[68], with numerous benefits (BOX 3). General surgical 
networks have complete national coverage and now encompass all surgical subspecialties [69]. These 
networks have the ability to deliver both multicentre observational and randomized research. For 
example, the randomized controlled ROSSINI trial43 was conducted across 21 hospitals to test the 
efficacy of a wound guard in preventing infection of the surgical site after major abdominal surgery. As 
a national portfolio trial in the UK, this trial was designed and conducted by surgical trainees, who 
recruited 760 patients ahead of schedule[70]. The MAStectomy Decisions Audit (MASDA) study is an 
ongoing multicentre observational study that is being led by breast surgery trainees; the aim of this 
study is to describe the current UK practice in multidisciplinary team decision-making for patients 
undergoing mastectomy [71]. Trainee networks can also expand into Europe, as exemplified by the 
cohort studies delivered by the ESCP, in which trainees participate at each level. 
 Medical students represent the next generation of potential surgical researchers and, 
therefore, starting their collaborative and research training at an early stage would be advantageous. 
Such a strategy would immerse the prospective surgeons in the culture of multidisciplinary trials at an 
early stage of their careers, thereby facilitating the identification of future surgical oncology leaders. 
In the UK, a national network involving students interested in surgical research has been granted 
funding by the Bowel Disease Research Foundation to train 40 senior medical students per year in the 
practical recruitment of patients into randomized trials [72]. This initiative will deliver a research-ready 
cohort of junior doctors across multiple specialties, who will subsequently transition into regional 
surgical research collaborations[73].  
 
[H1] Multidisciplinary working 
 [H2] The multidisciplinary team meeting 
In many countries, multidisciplinary team meetings and tumour boards have become embedded into 
day-to-day clinical practice as a way of improving and standardizing treatment decision-making. In one 
international survey of practice in the care of patients with breast cancer, excluding those in the USA, 
92% of respondents worked in a centre with a multidisciplinary team and, in over half of the 39 
countries surveyed in Eastern and Western Europe, multidisciplinary-team-led decision-making was 
mandatory[74] and trainee attendance was encouraged. In these meetings, all newly diagnosed 
patients with cancer, and specifically the management plan for these patients, are typically discussed 
by teams comprising medical oncologists, radiation oncologists, surgical oncologists, radiologists, 
interventional radiologists, nuclear medicine physicians, histopathologists and, importantly, trainees 
in these disciplines. Representatives of all four pillars of oncology are present and, therefore, local 
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standardization can be achieved whilst promoting a community-wide and culture-wide approach to 
treatment and instilling in trainees the importance of contributions from experts in other disciplines. 
Indeed, mutual respect and cross-disciplinary understanding of the different treatment options 
offered by each specialty should be incentivised and highly valued, facilitated by an exchange of data, 
ideas and new approaches to therapy.  
 Multidisciplinary teams can provide an important setting for multidisciplinary learning to take 
place, but no evidence exists on the extent to which trainees benefit from this learning opportunity, or 
whether dissemination of knowledge relating to various specialties occurs broadly and optimally among 
trainees. The financial costs associated with these meetings are high[75], but the meetings are credited 
with improving the outcomes of patients with cancer in the UK by reducing variations in clinical practice. 
Multidisciplinary team members believe that these meetings improve patient care and increase 
efficiency[76]. In addition, evidence supports the hypothesis that conducting such team meetings is 
associated with improved patient survival[77]. Involving patients in multidisciplinary  team meetings 
has also been shown to be of benefit in terms of their quality of life[78]. Thus, the adoption of 
multidisciplinary teams can improve both the consistency and quality of patient care, and generate 
opportunities for multidisciplinary learning and exchange of knowledge.  
 
[H2] Team working  
Multidisciplinary team involvement is now an expected requisite in public health-funded research. 
Development of personal skills is a key feature in the training of capable professionals within the team; 
however, a shortfall in formal training of budding oncologists in communication skills is well-
documented[79].  
In addition, the high rate of ‘burnout’ amongst health-care professionals involved in the treatment of 
patients with cancer is recognized[80], and the constant development of new anticancer therapies 
requires a lifelong commitment to continued professional learning and development.  
 Multidisciplinary teams are at the heart of public–private partnerships, collaborations and 
think-tanks. Gone are the days when specialists in a single discipline (such as medical oncology) would 
develop a new drug without collaborating with other professionals. Funding bodies expect integration 
of combination therapies, medical devices, radiotherapy and systemic therapy in order to understand 
the context of the treatment being proposed[81]. 
 Health-care systems globally must incorporate measures to reinforce mechanisms that reward 
multidisciplinary approaches to treating patients with cancer.  In the era of precision medicine, the 
multispecialty approach can have numerous effects, from enabling patients to receive the most-
appropriate treatment to delivering such treatments in a timely fashion. The best example of 
multidisciplinarity would be a combined specialty clinic in which patients would be jointly examined by 
professionals from two or more specialties[82]. Decreased time to diagnosis and decreased patient 
anxiety levels, and increased patient satisfaction are achieved in multidisciplinary clinics compared with 
other settings[78]. Collaborative care might also inspire multidisciplinary research and quality 
assurance [42]. An example of such multidisciplinary research is the PACE trial which randomizes 
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participants between surgery and stereotactic radiotherapy in early prostate cancer; recruitment has 
been shown to be possible between such different modalities within a multidisciplinary clinic context 
and quality assurance is an important consideration throughout the clinical trial [83].  
 
[H1] Conclusions  
Cancer care has undergone a technological revolution over the past 10 years, evolving from general 
specialties using techniques that had not changed for decades into highly specialized fields in which the 
pace of innovation threatens to outstrip the ability of medical professionals to educate their trainees in 
an integrated fashion. How these trainees are expected to keep up with advances relating to their own 
specialty, let alone the other three pillars of cancer care, is a pressing question that will only be 
addressed with an integrative training system (BOX 4 and TABLE 1).  
 This is an exciting time for all cancer-related medical specialties, and great strides have been 
made towards improving the outcomes for patients. This progress must be matched by a drive to train 
the next generation of oncologists in an integrated way that prepares them for the challenges ahead. 
Improving the training in all four pillars of cancer care is achievable, and many of the most striking 
opportunities require comprehensive knowledge of the other three pillars. For example, in radiation 
oncology, advanced technologies such as MR Linac[11], proton therapy[84] and molecular radiotherapy 
(for example, selective internal radiation therapy (SIRT)[8] and 223Ra therapy[85]) must be paired with 
state-of-the-art imaging, which requires cross-disciplinary input from many professional groups. With 
the increased precision of cancer-targeting, greater certainty about the location of the tumour and the 
area most at risk of recurrence are required. Functional imaging (such as multiparametric or whole-
body diffusion-weighted MRI and PET[86]), including novel tracers, will be crucial to this effort. The 
extent to which clinical oncology training can evolve to rapidly accommodate new advances and 
techniques will be integral to the success of efforts to nurture future oncology leaders — these efforts 
must start at medical school via provision of students with opportunities to explore the oncological 
specialties.  
 To continue the fast-paced improvements in cancer treatment, academically minded 
oncologists in all four specialties of cancer care must drive forward innovation and research, and 
mechanisms to integrate research and training need to be promoted. The broad range of skills acquired 
during dedicated research time will not only enhance the future academic output of the trainee 
oncologists, but the analytical and logical ways of thinking that such schemes promote will also augment 
the ability of health-care systems to manage and implement changes.  
 Cancer care requires mutual interdependence between a wide range of multidisciplinary 
colleagues, and the adoption of multidisciplinary team meetings is key to delivering the best possible 
care. Research, training, and patient care benefit from multidisciplinarity, and adoption of this approach 
will ensure that trainees of all four specialties in clinical oncology are ready to face the new challenges 
ahead together. 
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Box 1 | Professional organizations supporting multidisciplinary oncology training  
 
Multidisciplinary meetings 
 The British Uro-Oncology Group organizes annual meetings (predominantly for medical and 
clinical oncologists) and regional training sessions, and is involved in guideline development 
(http://www.bug.uk.com) 
 The British Thoracic Oncology Group organizes annual meeting, and assumes a teaching and 
advocacy role across lung cancer disciplines (www.btog.org) 
 
Multidisciplinary learning   
 The ECCO–AACR–EORTC–ESMO Workshop on Methods in Clinical Cancer Research (formerly 
known as Flims) includes European and US experts from all oncological specialties as wells as 
expert clinical trialists, statisticians and radiologists. The workshop represents a fertile 
environment in which clinical trial ideas can be considered from multiple expert perspectives 
(http://www.esmo.org/Conferences/Workshops-Courses/Methods-in-Clinical-Cancer-
Research-MCCR) 
 The ESMO school runs international multidisciplinary courses to enable trainees to learn 
effectively from and alongside other professionals 
(http://www.esmo.org/Conferences/Workshops-Courses) 
 
International organizations  
 European Society for Surgical Oncology (www.essoweb.org) 
 European Society for Radiotherapy and Oncology (www.estro.org/) 
 ESMO (www.esmo.org/) 
 
UK national organizations  
 The Clinical and Translational Radiotherapy Research Working Group (CTRad) is split into 
different workstreams aiming to deliver a cohesive response to the challenges of 
implementing both new technologies 58, 59 and new trials relating to radiotherapy. In 
addition, they provide a forum for trainees  to confidentially discuss a new clinical trial idea 
with a panel of experts (http://ctrad.ncri.org.uk). 
 In the Radiotherapy–Drug Combinations Consortium (RaDCom) leading UK laboratory 
researchers collaborate with the aim of delivering high-quality preclinical projects, which 




 Combined research agenda 
 Collaborations between academic centres supported by an industry partner 
 Synergistic Research and Development work 
 Financial, organisational and academic support for meetings and learning opportunities  
 
AACR, American Association for Cancer Research; ECCO, European CanCer Organisation; EORTC, 
European Organisation for the Research and Treatment of cancer.  
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Box 2 | Principles of ESMO22  
 To improve the quality of prevention, diagnosis, treatment, supportive and palliative care, 
as well as the follow-up of patients with malignant disorders 
 To advance the art, science, recognition, and practice of oncology 
 To disseminate knowledge in oncology to patients with cancer and the public 
 To educate and train persons involved in clinical cancer care and research 
 To promote education in oncology in order to ensure a high standard of qualification of 
medical oncologists within the multidisciplinary team 
 To facilitate equal access to optimal cancer care to all patients with cancer  
 To maintain liaisons with other oncology specialties, cancer leagues, universities, patient 
groups and, where appropriate, the pharmaceutical industry 
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Box 3 | Benefits of participation in trainee-led research collaborations 
 
For trainee 
 Experience in research methodology and data analysis 
 ‘Improved CV’ owing to inclusion of publications, presentations and posters 
 Acquisition of transferable skills, such as teamwork, leadership, management or public 
speaking 
 Experience in research administration 
 Helps trainees achieve excellence in training 
 
For patients 
 Improved quality of research 
 Increased awareness of patients’ needs when trainees frame the research question 
 
 For research 
 Improved quality of research 
 Improved recruitment through trainees 
 Increased number of surgical studies 
 Increased multicentre collaboration 
 
For region or training scheme 
 Improved reputation of scheme 
 Helps trainees achieve excellence in training 
 Increased research infrastructure in region 
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Box 4 | Proposed solutions to improve global oncology training 
 Formal training in complementary oncology disciplines 
 Adoption of competency-based training programmes to allow time for multispecialty training 
and research exposure  
 Embed research training into all oncology training schemes 
 Leverage efficiencies of e-learning programmes (such as ASCO’s Education Essentials for 
Oncology Fellows programme), online modules and simulation strategies 
(http://university.asco.org/education-essentials-oncology-fellows-eeof) 
 Reimbursement of health-care costs should favour multidisciplinary clinics and 
multidisciplinary decision-making mechanisms 
 Conferences and training days should prioritize contents related to multidisciplinary learning  
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Figure 1 | The four pillars of oncology. The importance of all four principal oncology specialties is 
depicted.  
 
Figure 2 | Examples of functional teams that benefit from strong interdisciplinary collaboration. 
Each umbrella shows an example of a functional team required to deliver the optimal package of care. 
All four specialties are equally important, although the shading within each umbrella represents the 
specialty that could be tasked with coordinating multidisciplinary work for each of the teams.   
 
Figure 3 | Academic career pathways for oncology. The progression of oncology trainees and the 
opportunities to gain academic experience during training is shown from left to right. The terminology 
shown is specific to the UK, but principles of training are common across Europe and North America. 





Table 1 | Unmet training needs and proposed solutions 
 
Unmet need Proposed solution 
Poor trainee knowledge of other pillars of 
oncology 
 
 Multidisciplinary clinics to facilitate 
multidisciplinary learning 
opportunities 
 Dedicated training time (for example, 
3–6 months) spent in other specialty 
 Structured training metrics to include 
appreciation of other specialty 
procedures and treatments 
Decision-making made in subspecialty silos  Multidisciplinary team meetings to 
promote joint decision-making 
 Multiprofessional clinics 
Inadequate exposure to research methodology 
and administration 
 Encourage trainees to take time out 
for research (formal research degree 
or fellowship to gain research skills) 
 Include integration with clinical trials 
units into research fellowships 
Few opportunities to gain laboratory 
experience before PhD 
 Short (1–2-month) laboratory 
experience programmes for medical 
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